Incyte (INCY) Income towards Parent Company (2010 - 2026)
Incyte (INCY) posted Income towards Parent Company of $303.3 million for Q1 2026, up 1.35% on a QoQ basis from $299.3 million in Q4 2025, and up 91.73% year-over-year from $158.2 million in Q1 2025.
Incyte (INCY) Income towards Parent Company (2010 - 2026) Analysis & Trends
Incyte's Income towards Parent Company history runs 17 years deep, the most recent figure standing at $303.3 million for Q1 2026.
- Quarterly Income towards Parent Company rose 91.73% year-over-year to $303.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 billion (up 6631.44% YoY) and the FY2025 annual result came in at $1.3 billion, up 3844.96% from the prior year.
- Income towards Parent Company was $303.3 million for Q1 2026 at Incyte, up from $299.3 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at $424.2 million in Q3 2025 and bottomed at -$444.6 million in Q2 2024.
- A 5-year average of $150.6 million and a median of $169.5 million in 2024 frame the typical range for Income towards Parent Company.
- Peak annual rise in Income towards Parent Company reached 681.22% in 2024, while the deepest fall reached 318.43% in 2024.
- Incyte's Income towards Parent Company stood at $28.5 million in 2022, then soared by 606.51% to $201.1 million in 2023, then increased by 0.07% to $201.2 million in 2024, then jumped by 48.74% to $299.3 million in 2025, then rose by 1.35% to $303.3 million in 2026.
- Business Quant data shows INCY's Income towards Parent Company at $303.3 million in Q1 2026, $299.3 million in Q4 2025, and $424.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Incyte | 23.47 Bn | 19.46 Bn | 1.17 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 303.33 Mn |
| Dec 31, 2025 | 299.28 Mn |
| Sep 30, 2025 | 424.17 Mn |
| Jun 30, 2025 | 405.00 Mn |
| Mar 31, 2025 | 158.20 Mn |
| Dec 31, 2024 | 201.21 Mn |
| Sep 30, 2024 | 106.46 Mn |
| Jun 30, 2024 | -444.60 Mn |
| Mar 31, 2024 | 169.55 Mn |
| Dec 31, 2023 | 201.08 Mn |
| Sep 30, 2023 | 171.27 Mn |
| Jun 30, 2023 | 203.55 Mn |
| Mar 31, 2023 | 21.70 Mn |
| Dec 31, 2022 | 28.46 Mn |
| Sep 30, 2022 | 112.78 Mn |
| Jun 30, 2022 | 161.43 Mn |
| Mar 31, 2022 | 37.99 Mn |
| Dec 31, 2021 | 563.86 Mn |
| Sep 30, 2021 | 181.74 Mn |
| Jun 30, 2021 | 149.46 Mn |